Display options
Cite
Helgason HH, Engwegen JY, Zapatka M, et al. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncol Lett. 2010;1(2):327-333doi: 10.3892/ol_00000058.
Helgason, H. H., Engwegen, J. Y., Zapatka, M., Cats, A., Boot, H., Beijnen, J. H., & Schellens, J. H. (2010). Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncology letters, 1(2), 327-333. https://doi.org/10.3892/ol_00000058
Helgason, Helgi H, et al. "Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer." Oncology letters vol. 1,2 (2010): 327-333. doi: https://doi.org/10.3892/ol_00000058
Helgason HH, Engwegen JY, Zapatka M, Cats A, Boot H, Beijnen JH, Schellens JH. Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer. Oncol Lett. 2010 Mar;1(2):327-333. doi: 10.3892/ol_00000058. Epub 2010 Mar 01. PMID: 22966303; PMCID: PMC3436443.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2010 Mar;1(2):327-333. doi: 10.3892/ol_00000058. Epub 2010 Mar 01.

Serum proteomics and disease-specific biomarkers of patients with advanced gastric cancer.

Oncology letters

Helgi H Helgason, Judith Y M N Engwegen, Mark Zapatka, Annemieke Cats, Henk Boot, Jos H Beijnen, Jan H M Schellens

Affiliations

  1. Division of Clinical Pharmacology, Department of Medical Oncology, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam.

PMID: 22966303 PMCID: PMC3436443 DOI: 10.3892/ol_00000058

Abstract

Gastric cancer is a commonly diagnosed solid tumor which is associated with a dismal prognosis making early diagnosis essential. Thus, this study aimed to identify novel biomarkers in gastric cancer. Serum of patients with advanced gastric cancer was collected according to a predefined schedule: prior to first-line chemotherapy with epirubicin (50 mg/m(2), day 1), cisplatin (60 mg/m(2), day 1) and capecitabine (1,000 mg/m(2), twice daily on days 1-14). The serum was collected serially before the treatment cycles and then analyzed by SELDI-TOF MS. Normal control subjects were matched according to age, gender and serum collection. Serum proteomic mass spectrometry data of all subjects were processed using the tbimass R-package and compared. We analyzed i) whether proteomic profile changes were associated with a response to chemotherapy and survival, and ii) whether changes in proteomic profiles occurring during the time period of chemotherapy were associated with tumor response. In total, 82 patients with adenocarcinoma of the stomach (mean age 57 years, males 69.5%) were treated with a mean number of five chemotherapy cycles. The overall tumor response rate, complete and partial remission combined, was 37%, median time to progression was 7 months (95% CI, 6-8) and median overall survival 11 months (95% CI, 9.5-12). By comparing 77 serum samples of patients with normal matched controls, we identified 32 proteins which discriminated the two groups. By selecting the most differentiating proteins, we built a classification model that correctly categorized 81% of the gastric cancer patients and 90% of the normal controls. Furthermore, we found a statistically significant correlation between the pre-treatment intensity of serum amyloid-α (SAA) and overall survival in gastric cancer patients, whereby a low intensity of SAA predicted a longer patient survival. A classification model, based on the 32 most discriminating proteins differentiating gastric cancer from normal controls, correctly classified subjects with relatively high sensitivity and specificity.

References

  1. Ann Surg. 2000 Sep;232(3):362-71 - PubMed
  2. Curr Opin Biotechnol. 2004 Feb;15(1):24-30 - PubMed
  3. Bioinformatics. 2005 Jul 15;21(14):3066-73 - PubMed
  4. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 - PubMed
  5. J Clin Oncol. 2006 Jun 20;24(18):2903-9 - PubMed
  6. J Clin Oncol. 2005 Sep 1;23(25):6220-32 - PubMed
  7. Cancer. 2000 Feb 15;88(4):921-32 - PubMed
  8. CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 - PubMed
  9. N Engl J Med. 2001 Sep 6;345(10):725-30 - PubMed
  10. Clin Chem. 2007 Apr;53(4):645-56 - PubMed
  11. World J Gastroenterol. 2006 Mar 14;12(10):1536-44 - PubMed
  12. Trends Pharmacol Sci. 2006 May;27(5):251-9 - PubMed
  13. Clin Chem. 2005 Dec;51(12):2229-35 - PubMed
  14. Cancer. 1990 Mar 1;65(5):1255-60 - PubMed
  15. BMC Med Genomics. 2009 Jan 19;2:4 - PubMed
  16. Lab Invest. 2007 Feb;87(2):161-72 - PubMed
  17. J Exp Ther Oncol. 2005;5(1):31-8 - PubMed
  18. Breast Cancer Res Treat. 2009 Jul;116(1):17-29 - PubMed
  19. J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 - PubMed
  20. Mol Cell Proteomics. 2006 Oct;5(10):1840-52 - PubMed
  21. Am J Med. 2003 Aug 15;115(3):191-5 - PubMed
  22. N Engl J Med. 2006 Jul 6;355(1):11-20 - PubMed
  23. Circ J. 2007 Feb;71(2):186-90 - PubMed
  24. BMC Bioinformatics. 2008 Feb 07;9:88 - PubMed

Publication Types